# Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-semaglutide-monotherapy-versus-placebo-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Christopher Sorli,Shin‐ichi Harashima,George Tsoukas,Jeffrey Unger,Julie Derving Karsbøl,Thomas K. Hansen,Stephen C. Bain |
| Citations | 723 |
| DOI | 10.1016/s2213-8587(17)30013-x |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://cronfa.swan.ac.uk/Record/cronfa31739 |
| OpenAlex ID | https://openalex.org/W2572398654 |
| PMID | 28110911 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Stephen C. Bain](https://scholariq.org/researchers/stephen-c-bain/)

## Paper journal

- [The Lancet Diabetes & Endocrinology](https://scholariq.org/journals/the-lancet-diabetes-and-endocrinology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.